These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

147 related items for PubMed ID: 355602

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Effect of baclofen on tardive dyskinesia.
    Gerlach J, Rye T, Kristjansen P.
    Psychopharmacology (Berl); 1978 Mar 01; 56(2):145-51. PubMed ID: 417365
    [Abstract] [Full Text] [Related]

  • 3. The relationship between parkinsonism and tardive dyskinesia.
    Gerlach J.
    Am J Psychiatry; 1977 Jul 01; 134(7):781-4. PubMed ID: 869056
    [Abstract] [Full Text] [Related]

  • 4. Sodium valproate in the treatment of levodopa-induced dyskinesia.
    Price PA, Parkes JD, Marsden CD.
    J Neurol Neurosurg Psychiatry; 1978 Aug 01; 41(8):702-6. PubMed ID: 355601
    [Abstract] [Full Text] [Related]

  • 5. Baclofen in the treatment of tardive dyskinesia.
    Nair NP, Yassa R, Ruiz-Navarro J, Schwartz G.
    Am J Psychiatry; 1978 Dec 01; 135(12):1562-3. PubMed ID: 31097
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Amantadine extended release for levodopa-induced dyskinesia in Parkinson's disease (EASED Study).
    Pahwa R, Tanner CM, Hauser RA, Sethi K, Isaacson S, Truong D, Struck L, Ruby AE, McClure NL, Went GT, Stempien MJ.
    Mov Disord; 2015 May 01; 30(6):788-95. PubMed ID: 25650051
    [Abstract] [Full Text] [Related]

  • 8. The long-acting dopamine receptor agonist cabergoline in early Parkinson's disease: final results of a 5-year, double-blind, levodopa-controlled study.
    Bracco F, Battaglia A, Chouza C, Dupont E, Gershanik O, Marti Masso JF, Montastruc JL, PKDS009 Study Group.
    CNS Drugs; 2004 May 01; 18(11):733-46. PubMed ID: 15330687
    [Abstract] [Full Text] [Related]

  • 9. AFQ056 in Parkinson patients with levodopa-induced dyskinesia: 13-week, randomized, dose-finding study.
    Stocchi F, Rascol O, Destee A, Hattori N, Hauser RA, Lang AE, Poewe W, Stacy M, Tolosa E, Gao H, Nagel J, Merschhemke M, Graf A, Kenney C, Trenkwalder C.
    Mov Disord; 2013 Nov 01; 28(13):1838-46. PubMed ID: 23853029
    [Abstract] [Full Text] [Related]

  • 10. Eltoprazine counteracts l-DOPA-induced dyskinesias in Parkinson's disease: a dose-finding study.
    Svenningsson P, Rosenblad C, Af Edholm Arvidsson K, Wictorin K, Keywood C, Shankar B, Lowe DA, Björklund A, Widner H.
    Brain; 2015 Apr 01; 138(Pt 4):963-73. PubMed ID: 25669730
    [Abstract] [Full Text] [Related]

  • 11. Tozadenant (SYN115) in patients with Parkinson's disease who have motor fluctuations on levodopa: a phase 2b, double-blind, randomised trial.
    Hauser RA, Olanow CW, Kieburtz KD, Pourcher E, Docu-Axelerad A, Lew M, Kozyolkin O, Neale A, Resburg C, Meya U, Kenney C, Bandak S.
    Lancet Neurol; 2014 Aug 01; 13(8):767-76. PubMed ID: 25008546
    [Abstract] [Full Text] [Related]

  • 12. Trial of dextromethorphan/quinidine to treat levodopa-induced dyskinesia in Parkinson's disease.
    Fox SH, Metman LV, Nutt JG, Brodsky M, Factor SA, Lang AE, Pope LE, Knowles N, Siffert J.
    Mov Disord; 2017 Jun 01; 32(6):893-903. PubMed ID: 28370447
    [Abstract] [Full Text] [Related]

  • 13. Randomized, placebo-controlled trial of ADS-5102 (amantadine) extended-release capsules for levodopa-induced dyskinesia in Parkinson's disease (EASE LID 3).
    Oertel W, Eggert K, Pahwa R, Tanner CM, Hauser RA, Trenkwalder C, Ehret R, Azulay JP, Isaacson S, Felt L, Stempien MJ.
    Mov Disord; 2017 Dec 01; 32(12):1701-1709. PubMed ID: 28833562
    [Abstract] [Full Text] [Related]

  • 14. Baclofen (Lioresal) in the treatment ofneuroleptic-induced tardive dyskinesia.
    Korsgaard S.
    Acta Psychiatr Scand; 1976 Jul 01; 54(1):17-24. PubMed ID: 782159
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Opicapone as an adjunct to levodopa in patients with Parkinson's disease and end-of-dose motor fluctuations: a randomised, double-blind, controlled trial.
    Ferreira JJ, Lees A, Rocha JF, Poewe W, Rascol O, Soares-da-Silva P, Bi-Park 1 investigators.
    Lancet Neurol; 2016 Feb 01; 15(2):154-165. PubMed ID: 26725544
    [Abstract] [Full Text] [Related]

  • 17. Tiapride in levodopa-induced involuntary movements.
    Lees AJ, Lander CM, Stern GM.
    J Neurol Neurosurg Psychiatry; 1979 Apr 01; 42(4):380-3. PubMed ID: 458486
    [Abstract] [Full Text] [Related]

  • 18. Simvastatin decreases levodopa-induced dyskinesia in monkeys, but not in a randomized, placebo-controlled, multiple cross-over ("n-of-1") exploratory trial of simvastatin against levodopa-induced dyskinesia in Parkinson's disease patients.
    Tison F, Nègre-Pagès L, Meissner WG, Dupouy S, Li Q, Thiolat ML, Thiollier T, Galitzky M, Ory-Magne F, Milhet A, Marquine L, Spampinato U, Rascol O, Bezard E.
    Parkinsonism Relat Disord; 2013 Apr 01; 19(4):416-21. PubMed ID: 23283428
    [Abstract] [Full Text] [Related]

  • 19. A Placebo-Controlled Trial of AQW051 in Patients With Moderate to Severe Levodopa-Induced Dyskinesia.
    Trenkwalder C, Berg D, Rascol O, Eggert K, Ceballos-Baumann A, Corvol JC, Storch A, Zhang L, Azulay JP, Broussolle E, Defebvre L, Geny C, Gostkowski M, Stocchi F, Tranchant C, Derkinderen P, Durif F, Espay AJ, Feigin A, Houeto JL, Schwarz J, Di Paolo T, Feuerbach D, Hockey HU, Jaeger J, Jakab A, Johns D, Linazasoro G, Maruff P, Rozenberg I, Sovago J, Weiss M, Gomez-Mancilla B.
    Mov Disord; 2016 Jul 01; 31(7):1049-54. PubMed ID: 26990766
    [Abstract] [Full Text] [Related]

  • 20. Baclofen in tardive dyskinesia patients maintained on neuroleptics.
    Stewart RM, Rollins J, Beckham B, Roffman M.
    Clin Neuropharmacol; 1982 Dec 01; 5(4):365-73. PubMed ID: 6130838
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.